Physician profile
Renata Block
NPI 1639129554
$103,305.15
in general payments reported to CMS, 2019-2025
24 companies · $8,423 in 2025
The $8,423 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,096 · 2022: $21K · 2023: $33K · 2024: $38K · 2025: $8,423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $37K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30K · Travel and Lodging: $6,399 · Food and Beverage: $6,072 · Education: $17.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $36,982.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29,625.00 |
| Travel and Lodging | $6,398.86 |
| Food and Beverage | $6,071.63 |
| Education | $17.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $29,359.69 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $20,032.38 | 2021-2025 | Winlevi, Absorica Ld |
| Genzyme Corporation | $17,869.40 | 2022-2025 | |
| Galderma Laboratories, L.P. | $14,940.15 | 2021-2025 | Aklief |
| Novartis Pharmaceuticals Corporation | $6,721.92 | 2021-2025 | Cosentyx |
| Leo Pharma INC. | $6,000.14 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,720.00 | 2023-2024 | Spevigo |
| Amgen INC. | $1,236.89 | 2024 | Otezla |
| Sanofi US Services INC. | $823.00 | 2025 | |
| Pfizer INC. | $701.89 | 2021-2024 | |
| Journey Medical Corporation | $649.64 | 2021-2023 | |
| Lilly USA, LLC | $595.38 | 2021-2025 | Taltz, Olumiant |
| Mayne Pharma Commercial LLC | $340.32 | 2023 | |
| Dermavant Sciences, INC. | $336.30 | 2023-2024 | Vtama |
| Abbvie INC. | $318.27 | 2021-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $170.74 | 2024 | Zoryve |
| Verrica Pharmaceuticals INC. | $125.00 | 2025 | Ycanth |
| Regeneron Healthcare Solutions, INC. | $111.89 | 2021-2024 | Dupixent |
| Incyte Corporation | $83.64 | 2024 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $52.90 | 2021-2024 | Arazlo, Jublia, Duobrii |
| Ucb, INC. | $39.76 | 2021-2024 | Bimzelx |
| Janssen Biotech, INC. | $35.52 | 2023-2024 | Tremfya, Stelara, Simponi |
| Convatec INC. | $23.26 | 2024 | |
| Organon LLC | $17.07 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renata Block listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.